PRGO - Galapagos Ratings Downgrade And Other News: The Good Bad And Ugly Of Biopharma
Galapagos Receives Rating Downgrade, Stock Skids
Galapagos NV (GLPG) stock was hit hard as Bank of America downgraded its rating to Sell. The latest downgrade comes after a couple of other such negative recommendations made by other stock research firms. The pharma company stock was recently downgraded by JPMorgan Chase & Co. which pulled its rating from Overweight to Neutral. Similarly, Credit Suisse Group lowered the rating from Outperform to Neutral and slashed the price target from $174 to $169. However, there was a silver lining as well as Stifel increased the price